Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NBI Focuses on Neurology, Immunology, CV, Cancer
February 16, 2004
- OTC NEWS IN BRIEF
February 16, 2004
- BUSINESS NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results
February 16, 2004
- WEBSITE NEWS
February 16, 2004
- Over 50% of Patients Think Bungyo Should Be Promoted: Survey
February 16, 2004
- 1st 3 Qtrs Business Results -1-
February 16, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results -2-
February 16, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2004
- New Drug Organization to Start with 9 Departments Responsible for Application Review
February 16, 2004
- WORLD NEWS IN BRIEF
February 16, 2004
- Chuikyo Talks Break Down on Expanding DPC System to Private Hospitals
February 16, 2004
- AnGes MG, Gene Design to Codevelop 3rd-Generation Decoy Products
February 16, 2004
- REGULATORY NEWS IN BRIEF
February 16, 2004
- New Glucose Chip Requires Very Small Amount of Blood: Dr Karube of TUT
February 16, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 16, 2004
- Gene Therapy for Alzheimer's Disease Successful in Mice
February 16, 2004
- Taxotere, Cisplatin Combination Therapy Prolongs Survival: Aventis
February 16, 2004
- Overview of US Drug Industry, Healthcare Presented: JPMA Seminar
February 9, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…